Royalty Report: Drugs, Therapeutic, Assay – Collection: 211862


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Therapeutic
  • Assay
  • Diagnostic
  • Disease
  • Drug Discovery
  • Viral Infection

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 211862

License Grant
Licensor grants to an exclusive license, subject to Licensors right to use Licensed Products for research activities, under the Licensed Technical Information, with the right to grant sublicenses to Sublicensees, to manufacture, market, use, sell and distribute the Licensed Products throughout the Territory and the non-exclusive right, with the right to grant sublicenses to Sublicensees, to use any Compound Trademark in connection with the manufacture, marketing, use, sale and distribution of Licensed Products only, in each case subject to, and in accordance with, the terms of this Agreement.
License Property
The Licensed Product means any and all transdermal patches for the administration of the Compound, either alone or in combination with other compounds, for use in the Field.

Licensor has developed, and owns the right to use, certain data and information pertaining to the synthetic steroid Nestorone(R) (17-acetoxy-16-methylene-19-norprogesterone).

Licensor and the manufacturer of Nestorone(R) have entered into an agreement for, among, other things, the supply of Nestorone(R), to manufacturers of products incorporating Nestorone(R), including products for use in the field of human reproductive health.

Nestorone and Elcometrine, is a progestin of the 19-norprogesterone group which is used as a hormonal contraceptive and in the treatment of endometriosis.

Endometriosis is a condition in which the layer of tissue that normally covers the inside of the uterus grows outside of it. Most often this is on the ovaries, fallopian tubes, and tissue around the uterus and ovaries; however, in rare cases it may also occur in other parts of the body.

The tradename registered is Nestorone(R).

Field of Use
The Field means human hormone replacement therapy or contraception.

IPSCIO Record ID: 255484

License Grant
Licensor grants an irrevocable, limited, exclusive, world-wide license to use Companion Diagnostic Tests as the rationale for and as an on-label indication for Endometriosis Therapeutic.
License Property
LICENSOR is engaged in the development of genetic tests for the determination of the existence and the predisposition of endometriosis and related conditions.

LICENSOR is the named assignee for several patent applications including nonprovisional US patent application SIN 12/120,322 to Kenneth Ward entitled 'Method of Administering a Therapeutic'.

Companion Diagnostic Tests mean any Test for the administration of a Therapeutic, the use, sale, or offer of sale of which would, but for this Agreement, constitute an infringement of the Patent Application referred to as 322 or any continuation, divisional, continuation in part, or foreign counterpart application claiming priority to the 322 Application, and any patent that may issue therefrom, collectively, the Test Patents.

Endometriosis is an often painful disorder in which tissue that normally lines the inside of your uterus — the endometrium — grows outside your uterus. Endometriosis most commonly involves your ovaries, fallopian tubes and the tissue lining your pelvis.

Field of Use
The field of use application is for the commercialization of assays and related services for the prediction of endometriosis, and other health concerns, in the infertility market.

IPSCIO Record ID: 288103

License Grant
The Licensor group, including Universities, grants an exclusive license agreement to patents for new drug development.

During the term of the license agreement and for two years thereafter, Licensee undertakes not to develop or commercialize any product that directly competes with any marketed product that is covered by the licensed technology.

License Property
The intellectual property is for NLS-1. a small molecule candidate, derived from natural products, for treatment of viral infections caused by influenza virus A.

With this agreement, Licensee became the exclusive licensee of 6 U.S. patents, 1 European Patent, 1 PRC patent, 1 Indian patent and 1 Japanese patent, as well as 1 pending US patent application. Two technologies are claimed in the patents Epigallocatechin Gallate Derivatives for Inhibiting Proteasome, and Pro-EGCG.

Field of Use
NLS-1 is under active development for the treatment of endometriosis.

Endometriosis is an often painful disorder in which tissue similar to the tissue that normally lines the inside of your uterus — the endometrium — grows outside your uterus. Endometriosis most commonly involves your ovaries, fallopian tubes and the tissue lining your pelvis.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.